Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
This article was originally published in The Tan Sheet
Executive Summary
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.
You may also be interested in...
FDA Commissioner Logjam Broken?: NDAC’s Wood May Be Nominee
The FDA commissioner search process appears to be focusing on Nonprescription Drugs Advisory Committee member and Vanderbilt University Vice Chancellor Alastair Wood, MD
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
Antihistamine OTC Switch: FDA Asking If Rx Products Have "Unique" Aspects
FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.